Narges Baluch

Pediatrics
3030 Childrens Way
San Diego, CA 92123

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision Management.

HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision Management.

Journal: Biomedicines
Published: November 20, 2025

A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine.

A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine.

Journal: Biomolecules
Published: July 25, 2025

The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment.

The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment.

Journal: Cancers
Published: May 09, 2023

Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.

Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.

Journal: Oncotarget
Published: September 12, 2022

The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy.

The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy.

Journal: Cancers
Published: June 14, 2021

Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.

Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.

Journal: Oncotarget
Published: May 29, 2021

3D Multicellular Stem-Like Human Breast Tumor Spheroids Enhance Tumorigenicity of Orthotopic Xenografts in Athymic Nude Rat Model.

3D Multicellular Stem-Like Human Breast Tumor Spheroids Enhance Tumorigenicity of Orthotopic Xenografts in Athymic Nude Rat Model.

Journal: Cancers
Published: May 08, 2021

Exposomal research in the context of birth cohorts: What have they taught us?

Exposomal research in the context of birth cohorts: What have they taught us?

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: June 01, 2020

Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane.

Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane.

Journal: BMC cancer
Published: October 29, 2018

Erratum to: The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review.

Erratum to: The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review.

Journal: Journal of cell communication and signaling
Published: August 28, 2017

The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review.

The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review.

Journal: Journal of cell communication and signaling
Published: July 04, 2017

Combination therapy in combating cancer.

Combination therapy in combating cancer.

Journal: Oncotarget
Published: October 19, 2016
Showing 1-12 of 16

Last Updated: 09/26/2026